Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | EED | O75530 | 4/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16388972 | 1.00 | DRD2 (0.41) | DRD2DRD3HTR2CEEDHTR1A | |
| SCHEMBL415651 | 0.78 | HTR2C (0.39) | DRD2HTR2CHTR1A | |
| SCHEMBL4650091 | 0.76 | HTR2C (0.38) | HTR2C | |
| SCHEMBL2049735 | 0.76 | DRD2 (0.53) | DRD2HTR2CHTR1A | |
| SCHEMBL29905114 | 0.76 | DRD2 (0.53) | DRD2HTR2CHTR1A | |
| SCHEMBL15577042 | 0.76 | HTR2C (0.62) | HTR2CHTR1AHTR7 | |
| SCHEMBL19953487 | 0.76 | DRD2 (0.41) | DRD2DRD3HTR2CEEDHTR1A | |
| SCHEMBL13198466 | 0.76 | HTR2C (0.62) | HTR2CHTR1AHTR7 | |
| SCHEMBL22963773 | 0.76 | HTR2C (0.38) | DRD2HTR2CHTR1A | |
| SCHEMBL1150762 | 0.76 | DRD2 (0.49) | DRD2DRD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190763-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230190763-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-22 | — | — | US | disclosed |
| US-10745404-B2 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20180079755-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20180079755-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-9802938-B2 | Sulfamoylating reagents | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150353555-A9 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150080573-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-8933225-B2 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353555-A9 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | SULT1E1, SULT1A1, ALDH18A1 | DRD2 4691/4885DRD3 4681/4885HTR2C 3891/4885 |
| US-10745404-B2 | Process for the synthesis of E1 activating enzyme inhibitors | SULT1E1, SULT1A1, STS | DRD2 4622/4885DRD3 4604/4885HTR2C 3639/4885 |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | SULT1E1, SULT1A1, ALDH18A1 | DRD2 4691/4885DRD3 4681/4885HTR2C 3891/4885 |
| US-20150080573-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | SULT1E1, SULT1A1, ALDH18A1 | DRD2 4691/4885DRD3 4681/4885HTR2C 3891/4885 |
| US-20230190763-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | PTAFR, PDGFRA, PDGFRB | DRD2 2388/4885DRD3 2931/4885HTR2C 762/4885 |
| US-20180079755-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | SULT1E1, SULT1A1, ALDH18A1 | DRD2 4695/4885DRD3 4677/4885HTR2C 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.